H. Lee Moffitt Cancer Center and Research Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer \[clinical stage IA-IB (cT1a-T2aN0), \<4cm diameter\].
If surgical resection is recommended, patient will undergo surgery at Moffitt Cancer Center.
If a definite tissue diagnosis is obtained and stereotactic body radiotherapy (SBRT) is the recommended treatment instead of surgery, the SBRT will be delivered at Moffitt Cancer Center.
\>18 years old, male or female.
ECOG performance status 0-1.
Agree to participate in the follow-up protocol.
Any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma).
Ability to understand and the willingness to sign a written, informed consent document.
You may not be if
Participants who are actively receiving any cancer treatment.
Participants with uncontrolled intercurrent illness.
Prior lung cancer within 5 years.
Current active other major cancer except non-melanoma skin cancer.
Patients with pure ground glass opacities (nodules) or hilar masses.
Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma).
Metastatic nodule (suspected) in the lung from an extrapulmonary cancer.
Patient unable to provide informed consent.
Prisoner or incarcerated individual.
For surgical patients, a R1 or R2 resection.
Clareo Health | Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
